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H E A L T H  A N D  M E D I C I N E
ECRG4 regulates neutrophil recruitment and CD44 
expression during the inflammatory response to injury
Robert A. Dorschner1*, Jisook Lee2, Olga Cohen2, Todd Costantini2,  
Andrew Baird2, Brian P. Eliceiri2
The complex molecular microenvironment of the wound bed regulates the duration and degree of inflammation 
in the wound repair process, while its dysregulation leads to impaired healing. Understanding factors controlling 
this response provides therapeutic targets for inflammatory disease. Esophageal cancer–related gene 4 (ECRG4) 
is a candidate chemokine that is highly expressed on leukocytes. We used ECRG4 knockout (KO) mice to establish 
that the absence of ECRG4 leads to defective neutrophil recruitment with a delay in wound healing. An in vitro 
human promyelocyte model identified an ECRG4-mediated suppression of the hyaluronic acid receptor, CD44, a 
key receptor mediating inflammation resolution. In ECRG4 KO mouse leukocytes, there was an increase in CD44 
expression, consistent with a model in which ECRG4 negatively regulates CD44 levels. Therefore, we propose a 
previously unidentified mechanism in which ECRG4 regulates early neutrophil recruitment and subsequent 
CD44-mediated resolution of inflammation.
INTRODUCTION
Cutaneous wound repair is a model of tightly controlled inflammation. 
Early inflammatory responses mediate hemostasis, recruitment of 
proreparative myeloid cells, and wound debridement to support the 
revascularization and proliferative phase of wound healing (1). Dis-
ruption of this inflammation response is associated with delayed 
wound closure, infection, and scarring (1–3). Therefore, understand-
ing the mechanisms that regulate the degree and duration of the inflam-
matory response is critical for understanding and treating disease.
Injured tissues rapidly recruit leukocytes to clear pathogens and 
prepare the wound bed for tissue repair. This process involves some 
well-described chemokines, such as CXCL1 (4), CXCL2 (4), CXCL5 
(5), and CXCL8 (6), and is further regulated by factors generated in 
the complex molecular environment of the wound. For example, 
proteases activate latent chemokines, such as chemoattractants gen-
erated in the complement cascade, and degradation of extracellular 
matrix components produces biologically active molecules, such as 
hyaluronan fragments (7, 8). These products mediate the recruitment 
and activation of leukocytes and stromal cells. Some receptors, such 
as the Toll-like receptor (TLR) family, amplify inflammation in 
response to damage-associated molecular patterns and pathogen- 
associated molecular patterns present in the wound, while others 
respond by tempering the inflammatory response. For example, ac-
tivation of CD44 by hyaluronic acid (HA) fragments released from 
injured tissue modulates TLR signaling and can decrease inflamma-
tory responses and prevent septic shock (9–11). CD44 is also im-
portant for resolving inflammation at sites of injury, a requirement 
for wound healing to progress to the proliferative phase. In injury 
models, such as cutaneous wounds (2), pneumonia (12), non-
infectious lung injury (13), and myocardial infarction (14), loss of 
CD44 expression leads to increased and prolonged inflammation, 
exuberant leukocyte recruitment, failure to clear apoptotic neutro-
phils, and increased scarring and fibrosis (2, 7, 9, 12–15). Under-
standing the complex interaction of wound products and cellular 
receptors that govern the choreography of wound healing phase 
transitions is important for addressing poorly healing wounds and 
informs treatment of other inflammatory disorders.
Esophageal cancer–related gene 4 (ECRG4) is a membrane- 
tethered protein that is widely expressed in normal tissues and 
highly expressed on the surface of quiescent human granulocytes 
(16–18). ECRG4 was first described as an epigenetically regulated 
gene whose expression is suppressed in several cancer types (19–21), 
including esophageal cancer. Recent studies indicate that it may 
promote leukocyte recruitment, with its down-regulation in cancer 
contributing to escape from immunosurveillance (17, 22). ECRG4 
physically associates with TLR4 (23), while proteolytic processing 
releases it from the cell surface (17, 24). Soluble ECRG4 binds various 
scavenger receptors, including LOX-1 (25), and regulates phospho-
rylation of the nuclear factor B (NF-B) transcription factor 
(16, 23). In murine tumor models, the ability of soluble ECRG4 to 
increase the recruitment of inflammatory cells is dependent on 
thrombin cleavage (17). In humans with severe burn injury, ECRG4 
is shed from circulating neutrophils, while restoration of cell surface 
ECRG4 expression correlates with recovery (24). These observations 
suggest that ECRG4 has a role in regulating specific inflammatory 
responses, although its function in injury has not been determined 
in ECRG4 knockout (KO) mice. Here, we propose a previously un-
identified mechanism in which the amplification of early neutrophil 
recruitment and CD44 expression in the wound bed can be regulated 
by proteolytic processing of the leukocyte chemokine ECRG4.
RESULTS
ECRG4 KO delays early wound closure and impairs initial 
neutrophil recruitment
To determine whether ECRG4 is a functional mediator of the wound 
healing response, ECRG4 KO and wild-type (WT) mice were sub-
jected to splinted full-thickness excisional wounds. The wound area 
was measured daily to assess wound closure kinetics. ECRG4 KO 
mice had a notable, and statistically significant, delay in early wound 
closure compared to WT mice, which began at post-wound day 1 
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(WT 22.5 ± 2.4 mm2 versus KO 30.2 ± 0.7 mm2) and persisted until 
day 9 (WT 6.8 ± 4.7 mm2 versus KO 15.6 ± 4.2 mm2) (Fig. 1, A and B). 
To visualize changes in the rate of wound closure, we plotted these 
data as the change in wound area over time (fig. S1A). This highlighted 
a slower initial rate of wound closure in ECRG4 KO mice after injury 
that subsequently recovered to the rate of WT mice by day 3. This 
represents the inflammatory phase of wound healing, suggesting a 
role for ECRG4 in regulating the initial inflammatory response. We 
examined the recruitment of Gr1+ granulocytes at the margin of 24-hour 
wounds and observed decreased Gr1+ staining in the ECRG4 KO mice 
compared to WT controls (Fig. 1C). To quantify the ECRG4-mediated 
defect in granulocyte recruitment, we used flow cytometry to im-
munophenotype single-cell suspensions of dissociated skin from 
the margins of ECRG4 KO versus WT wounds (26). Flow cytometric 
analyses of CD45+ cells from the wound margins of post-injury day 1 
animals demonstrated a ~14-fold increase in CD45+CD11b+Ly6G+ 
neutrophils in WT mice compared to uninjured skin, which was not 
seen in ECRG4 KO mice at the same time point (Fig. 1D, top). In 
contrast, there was no significant difference between the ECRG4 KO 
and WT wound neutrophil numbers at day 3 (Fig. 1D, bottom). This 
is the time at which the ECRG4 KO wound closure rate approaches 
that of WT mice (fig. S1A). There was also no difference in neutro-
phil populations between uninjured ECRG4 KO and WT skin. These 
findings are the first to use an ECRG4 KO mouse to establish the 
functional significance of ECRG4 in mediating neutrophil recruit-
ment in the inflammatory phase of injury response.
A
C D
B
Fig. 1. ECRG4-deficient mice have delayed wound closure and neutrophil recruitment. To assess the role of ECRG4 in the cutaneous inflammatory response to injury, 
we examined wound healing as a model of tightly regulated inflammatory responses. (A) Splinted excisional wounds were created on the dorsal skin of ECRG4 KO and 
WT littermates. Wound area was measured daily [representative data from three separate experiments, n = 6 mice per group, two-way analysis of variance (ANOVA), 
P < 0.0001; Bonferroni posttest, *P < 0.05, **P < 0.01, and ***P < 0.001]. (B) Representative images of wounds at various time points. Photo credit: Robert A. Dorschner, 
UCSD. (C) Excisional wounds in ECRG4 WT (top row) or KO mice (bottom row) were harvested for immunohistochemistry at 24 hours, and infiltration of Gr1+ granulocytes 
(arrows) was assessed. Two representative images from ECRG4 WT and KO wound margins are shown; scale bars, 500 m (n = 3 per group). (D) Neutrophil recruitment to 
the full-thickness cutaneous wound was quantified using a protocol for preparing single-cell suspensions via partial enzymatic digestion followed by flow cytometry. 
Neutrophils were identified as CD45+CD11b+Ly6G+ cells in day 1 (top) and day 3 (bottom) excisional wounds (n = 3 to 4 mice per group; **P < 0.01 and *P < 0.05). ns, not 
significant.
Dorschner et al., Sci. Adv. 2020; 6 : eaay0518     11 March 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
3 of 11
ECRG4 regulates neutrophil recruitment to an aseptic injury
To define the role of ECRG4 in mediating leukocyte recruitment in 
the inflammatory phase of tissue response, we used subcutaneous im-
plantation of polyvinyl alcohol (PVA) sponge, a well-characterized 
in vivo model of sterile inflammation and foreign body reaction 
(27–29). Because infiltrating leukocytes can be harvested from PVA 
sponges without the need for enzymatic preparation, the cellular 
infiltrate was directly immunophenotyped by flow cytometry. The 
24-hour inflammatory infiltrate included subsets of CD11b+ leuko-
cytes that could be differentiated by their expression of Ly6C, includ-
ing CD11b+Ly6Cint neutrophils and CD11b+Ly6Chigh inflammatory 
macrophages (Fig. 2, A to C), as demonstrated by Daley, Dunay, 
and Gutierrez (27, 30, 31) and confirmed in Fig. 2F. ECRG4 KO mice 
recruited half the number of total CD11b+Ly6C+ cells to the site of 
injury at 24 hours compared to their WT littermates (Fig. 2A). Further 
analysis of this population revealed a threefold decrease in the infil-
tration of CD11b+Ly6Cint neutrophils in the ECRG4 KO mice (Fig. 2B), 
whereas no significant changes in the recruitment of CD11b+Ly6Chigh 
macrophages were observed (Fig. 2C). We further investigated the 
immunophenotype of the infiltrate at days 3 and 7 to identify any 
changes at these later time points. Similar to the wound (Fig. 1D), 
there was no difference in neutrophil recruitment between the WT 
and ECRG4 KO mice at day 3 (fig. S1B) or day 7 (fig. S1C). Because 
the early wound environment is rich in thrombin and thrombin acts 
upon ECRG4 to release a biochemically active C-terminal peptide, 
CT16 (Fig. 2D) (16), that recruits leukocytes in a tumor model (17), 
we examined whether CT16 could increase leukocyte recruitment to a 
24-hour injury. PVA sponges were loaded with 2 g of sterile syn-
thetic CT16 peptide or vehicle before implantation. We found that 
CT16 specifically increased CD11b+Ly6Cint neutrophil recruitment 
by 35% at 24 hours (Fig. 2E). There was no difference in Ly6Clow macro-
phages or Ly6Chigh inflammatory macrophages at this time point. 
These results demonstrate that ECRG4 is important for early neutro-
phil recruitment and support the role of ECRG4 as a novel protease- 
activated mediator of neutrophil recruitment in cutaneous injury.
Leukocyte production and their antimicrobial activity are 
not impaired in ECRG4 KO mice
We examined the leukocyte populations in blood and bone marrow to 
assess whether ECRG4 deficiency affected leukocyte production as a 
contributor to the decreased neutrophil numbers at the site of injury. 
Hemograms performed on the peripheral blood from uninjured mice 
demonstrated no differences between the circulating leukocyte popu-
lations of WT and ECRG4 KO mice (Fig. 3A). Similarly, flow cytometric 
A
D
F
E
B C
Fig. 2. ECRG4 deficiency impairs neutrophil response to an aseptic injury. The PVA aseptic injury model was used to model inflammatory responses at 24 hours. CD11b+ 
subpopulations were defined on the basis of their differential expression of Ly6C: CD11b+Ly6Clow patrolling macrophages, CD11b+Ly6Cint neutrophils, and CD11b+Ly6Chigh 
inflammatory monocytes and macrophages. Quantification of (A) CD11b+Ly6C+ total, (B) CD11b+Ly6Cint, and (C) CD11b+Ly6Chigh cells recruited at day 1 is shown (n = 9 to 
12 mice per group; *P < 0.05). (D) The ECRG4 protein contains several domains, including a well-characterized thrombin cleavage domain, which releases the CT16 (ECRG4133–148) 
peptide from the C terminus. (E) The addition of CT16 to the PVA sponge (2 g per sponge) increased recruitment of CD11b+Ly6Cint neutrophils at 24 hours, while CD11b+ 
Ly6Clow and CD11b+Ly6Chigh populations were not significantly different at this time point (n = 4; *P < 0.05). (F) Comparison of the CD11b+Ly6C gating strategy to the CD45+ 
CD11b+Ly6G+ strategy for identifying neutrophils demonstrated equivalency in 24-hour PVA infiltrates and confirmed the decrease in ECRG4 KO neutrophil recruitment (n = 3).
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analysis of bone marrow from uninjured mice demonstrated no dif-
ference in the composition or numbers of mature CD11b+Ly6C+ cell 
subsets (Fig. 3B). The composition of the ECRG4 KO mouse hema-
topoietic system was further analyzed by flow cytometry to assess 
populations of LSK stem cells and various progenitors of mature 
myeloid cells (Fig. 3, C and D). There were no differences in LSK 
hematopoietic stem cells (HSCs), long-term (LT)–HSCs, short-term 
(ST)–HSCs, multipotent progenitors (MPP), or LK myeloid progenitor 
cells (Fig. 3, E and F). Together, these data indicate that the lack of 
neutrophils seen at the site of injury in ECRG4 KO mice is not due 
to an impaired hematopoietic system, but a defect in local neutro-
phil recruitment. When we assessed the ability of ECRG4 KO mice 
to kill the pathogen, Staphylococcus aureus, in blood, no functional 
defect in leukocyte antimicrobial activity was observed (Fig. 3G). 
There was no difference in the capacity for whole blood from either 
ECRG4 KO mice or their WT littermates to kill methicillin-resistant 
S. aureus (MRSA) as assessed ex vivo. This indicates that there is no 
defect in the antimicrobial function of ECRG4-deficient leukocytes.
Constitutive expression of ECRG4 reprograms leukocyte 
transcriptional activity in vitro
To assess the effect of ECRG4 on gene expression in an in vitro model 
of leukocytes, we performed an RNA sequencing (RNA-seq) analy-
sis on HL60 human promyelocyte cells engineered to constitutively 
(10%)
Fig. 3. ECRG4 deficiency does not affect myelopoiesis or leukocyte antimicrobial function. (A) Leukocyte populations in uninjured ECRG4 KO and WT mice were assessed 
for underlying deficits. Hemograms of blood showed no significant difference in populations between uninjured ECRG4 KO (white bars) and WT (black bars) mice (n = 8 mice 
per group). (B) Flow cytometric analysis of bone marrow from uninjured ECRG4 KO (white bars) and WT (black bars) mice showed no significant difference between populations 
of CD11b+Ly6Clow, CD11b+Ly6Cint, and CD11b+Ly6Chigh cells (n = 9). HSC compositions were compared between the WT and ECRG4 KO bone marrow using flow cytometry. 
(C) Schematic of the lineage distinctions for HSCs and hematopoietic progenitor cells evaluated. (D) Lin− cells from healthy ECRG4 KO or WT bone marrow (left) were gating on 
the c-Kit+Sca1+ LSK population (middle), which was then differentiated by CD48 and CD150 expression (right) to identify long-tem (LT) HSC, short term (ST) HSC, and multipotent 
progenitor (MPP) populations. (E) There was no detectable difference in LSK HSCs (Lin−c-Kit+Sca1+), including no difference in LT HSC, ST HSC, or MPP subpopulations. 
(F) In addition, there was no difference in numbers of LK HPCs (Lin−c-Kit+Sca1−), which include common myeloid progenitor (CMP), megakaryocyte/erythrocyte progenitor 
(MEP), and granulocyte/macrophage progenitor (GMP) populations that give rise to all nonlymphoid myeloid cells (n = 8 mice per group). (G) The antimicrobial function of 
ECRG4 KO leukocytes was compared to WT mice in whole blood for their ability to kill MRSA. USA300 LAC [106 colony-forming units (CFU)/ml] was inoculated into fresh whole 
blood and incubated at 37°C for 3 hours, and the remaining colonies were enumerated, revealing no difference in antimicrobial function (n = 3 mice per group).
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express ECRG4. In a comparison with vector control HL60 cells, 
1638 genes were up-regulated and 1632 were down-regulated in cells 
constitutively expressing ECRG4 (data file S1). Both Gene Ontology 
analysis of biochemical processes and a KEGG (Kyoto Encyclopedia 
of Genes and Genomes) pathway visualization analysis demonstrated 
a number of biochemical pathways affected by the constitutive ex-
pression of ECRG4 that are important for inflammation and injury 
response (Fig. 4A and table S1).
The pathway most affected by the expression of ECRG4 in the 
KEGG analysis was the category of proteoglycans in cancer (Fig. 4A), 
which included changes in the expression of the HA receptor, CD44, 
and its signaling pathways (Fig. 4B and fig. S2). We validated a 
number of targets with potential relevance to the ECRG4-dependent 
inflammatory response defect in ECRG4 KO mice by flow cytometry 
(fig. S3), and cell surface CD44 was the most markedly altered. Given 
the deficit in neutrophil recruitment and wound healing seen in the 
ECRG4 KO mouse and the importance of CD44 in regulating leuko-
cyte migration, inflammation, and TLR signaling (2, 9–11, 13, 14, 32), 
we hypothesized that ECRG4 may regulate the expression of CD44. 
Using these HL60 cells in vitro, we verified the RNA-seq data with 
quantitative polymerase chain reaction (PCR) to measure mRNA and 
flow cytometry to measure surface protein (Fig. 4, C and D). Delivery 
of ECRG4 leads to a decrease of cell surface CD44 protein in HL60 
cells (Fig. 4C) and CD44 gene expression (Fig. 4D) compared to control 
cells. On the basis of the observation that shed ECRG4 peptide in-
creases neutrophil recruitment in vivo (Fig. 2E), we determined 
whether soluble ECRG4 affected CD44 expression. Incubation of 
naïve HL60 cells with the conditioned media of ECRG4-expressing 
cells, but not control cells, decreased CD44 surface protein expres-
sion (Fig. 4E). These results suggest that soluble ECRG4 can nega-
tively regulate CD44 expression in vitro.
CD44 expression is increased on ECRG4 KO  
mouse neutrophils
On the basis of the observation that increased expression of ECRG4 
down-regulated CD44 on myelocytes in vitro, we sought to deter-
mine whether the loss of ECRG4 in KO mice affected CD44 on leuko-
cytes in vivo. Using a flow cytometric analysis of uninjured mice, 
ECRG4 KO mice demonstrated a 57% increase in the expression of 
CD44 on blood neutrophils compared to WT controls (Fig. 5, A and C), 
with no difference in the overall number of CD44+ neutrophils 
(Fig. 5B). In bone marrow from uninjured mice, we observed an 
increase in CD44 surface expression on ECRG4 KO neutrophils 
(22.7% increase; Fig. 5, D and F) compared to WT mice, with no 
significant difference in the number of CD45+ cells or CD11b+Ly6G+ 
neutrophils (Fig. 5E and fig. S4). This increased CD44 expression 
on ECRG4 KO leukocytes, particularly neutrophils, correlates in-
versely with the loss of CD44 seen on myeloid cells overexpressing 
ECRG4 in vitro and supports a role for ECRG4 in the negative reg-
ulation of CD44 expression on neutrophils.
ECRG4 and CD44 expression are inversely correlated 
in the mouse wound
On the basis of the in vitro and in vivo data demonstrating that ECRG4 
negatively regulates CD44 expression on leukocytes, we evaluated 
the expression of these genes over the entire course of wound heal-
ing in mouse skin. Previous studies by our group demonstrated that 
ECRG4 expression remains low for the first 3 days after cutaneous 
injury and then increases with a peak of gene expression at day 7, 
when the wound is transitioning from the proliferative to the re-
modeling phases of repair (33). We reanalyzed the same gene ex-
pression database of cutaneous wound repair (34) and found that, 
as predicted, CD44 gene expression rapidly increased after injury 
and peaked at 24 hours before gradually returning to its baseline 
expression (Fig. 5G). As reported by Shaterian et al., ECRG4 ex-
pression remained low until day 3, when it increased until day 7, 
and then gradually decreased toward baseline (Fig. 5H). To compare 
these changes, expression was normalized to their relative expression 
at time 0 before injury and assessed together (Fig. 5I). The inverse 
relationship between ECRG4 and CD44 expression in the murine 
cutaneous wound supports a model wherein ECRG4 negatively reg-
ulates CD44 to mediate the inflammatory response to cutaneous 
injury.
DISCUSSION
This study demonstrates a role for leukocyte ECRG4 as a factor that 
amplifies neutrophil recruitment to site of injury and regulates their 
expression of CD44. Coordination of inflammation is an essential 
component of injury response and effective wound healing. The re-
cruitment of neutrophils is a hallmark of the early wound response 
during hemostasis and the initial inflammatory phase, which pre-
pares the wound bed for subsequent proreparative leukocytes to 
mediate revascularization, reepithelialization, and tissue repair. The 
regulation of CD44 by ECRG4 in this process is consistent with the 
role of CD44 in resolving inflammatory processes, including limit-
ing neutrophil accumulation at sites of injury (2, 14), tempering 
TLR-mediated inflammatory responses (9–11), and enhancing phago-
cytosis (15) and efferocytosis (13), all of which are central to coordi-
nated wound healing.
This study uses a novel genetic KO mouse model to identify 
ECRG4 as a previously unrecognized regulator of inflammation in 
cutaneous injury. Analysis of these wounds demonstrated defective 
recruitment of neutrophils in the ECRG4 KO wound at 24 hours 
after injury, which was confirmed in an aseptic injury model. We 
evaluated whether a thrombin-mediated ECRG4 peptide could 
contribute to this effect, because it has been shown to enhance leuko-
cyte recruitment in tumor models. The CT16 peptide of ECRG4 
was able to increase early in vivo neutrophil recruitment to an aseptic 
injury, demonstrating that an ECRG4 peptide generated in the 
thrombin-rich inflammatory microenvironment of the wound bed 
amplifies neutrophil responses. These data define ECRG4 as a reg-
ulator of the inflammatory response to injury, including early neu-
trophil recruitment and wound healing.
To further define the effects of ECRG4 seen in leukocytes in vivo, 
we used HL60 cells as an in vitro myeloid cell model. We identified 
the alteration of a number of key inflammatory processes in cells 
constitutively expressing ECRG4, including innate immune signaling 
(TLR signaling, NF-B cascade, and cytokine signaling), apoptosis, 
and cell cycle. Among these, CD44 expression was completely abro-
gated at the transcriptional and protein expression levels in the HL60 
cells expressing ECRG4. This effect is mediated, at least in part, by 
a soluble factor from the ECRG4-expressing cells, as their condi-
tioned media decreased CD44 expression on naïve cells. These re-
sults indicate that ECRG4 can function in an autocrine or paracrine 
fashion to affect transcriptional programming of cells in the local 
inflammatory milieu. While it has been shown that various ECRG4 
peptides are released into the media of cells constitutively expressing 
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ECRG4 (16), the precise mechanism for its suppression of CD44 
expression is unknown. We show that the capacity for ECRG4 to 
regulate CD44 expression occurs in vivo based on the increased 
CD44 expression observed on neutrophils from ECRG4 KO mice 
compared to WT mice and the inverse expression of these genes in 
the murine wound. These changes were due to an increase in CD44 
expression per cell and not a change in the overall number of CD44+ 
cells in blood or bone marrow, supporting the role of ECRG4 as a 
negative regulator of CD44.
These findings define ECRG4 as a mediator of CD44 expression 
and support a model where loss of ECRG4 at the site of injury in-
creases CD44 expression, suggesting a novel mechanism for the 
regulation of the inflammatory response in cutaneous injury. In 
these studies, we demonstrate a role for ECRG4 in both cutaneous 
A B
C
D E
Fig. 4. Constitutive expression of ECRG4 in HL60 promyelocytes reprograms inflammatory response pathways. RNA-seq was performed on HL60 promyelocytes 
constitutively expressing ECRG4. (A) The top differentially expressed pathways, as determined by KEGG pathway visualization, included pathways central to inflammato-
ry responses. (B) The top differentially expressed category was proteoglycan signaling, with the CD44 pathway having the most genes altered, as demonstrated in the 
heat map (N.D., not detected). (C) CD44 cell surface protein was evaluated on these cells via flow cytometry, gating on green fluorescent protein–positive (GFP+) cells and 
measuring CD44 mean fluorescence intensity (data are representative of five separate experiments with three replicates each; ***P < 0.001). (D) Confirmation of CD44 
gene expression in the H60 cells constitutively expressing ECRG4 demonstrated loss of CD44 transcription via quantitative PCR (data are representative of five separate 
experiments with three replicates each). The ability of a soluble factor from the cells constitutively expressing ECRG4 to suppress CD44 was demonstrated by the addition 
of conditioned media (CM) to naïve parental HL60 cells. (E) Decreased CD44 cell surface protein expression was determined by flow cytometry (data are representative of 
five separate experiments with three replicates each). MFI, mean fluorescence intensity.
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wounds and the subcutaneous PVA implant, which represent 
two distinct models of inflammation. This also appears to be 
a previously unrecognized regulatory pathway of inflammation, 
as CD44 itself is known to play an important role in regulating 
the inflammatory response to a variety of injuries, including cuta-
neous wounds (2), pneumonia (12), noninfectious lung injury 
(13), and myocardial infarction (14). Neutrophil recruitment 
and TLR responses are central to the cutaneous host defense 
against infection. Several investigators have found that activa-
tion of CD44 by fragments of HA released from injured tissue 
modulates TLR signaling, decreases inflammatory responses, 
and prevents excessive systemic inflammation, such as septic 
shock (9–11). Others have shown that decreased CD44 enhances 
neutrophil accumulation at the site of injury (2, 14). Together, 
these data infer that an ECRG4-CD44 pathway may be important 
for host defense.
Our findings demonstrate that ECRG4 mediates the early in-
flammatory response and regulates CD44 expression. In addition to 
this ability, previous studies have shown that cell surface ECRG4 can 
be processed by proteases, like thrombin, at the site of inflammation 
or tumor to release peptides with proinflammatory activity. While 
intact ECRG4 associates with TLR4 (16, 23), its various peptide frag-
ments increase phosphorylation of p65 (16, 17), bind scavenger 
receptors, and activate NF-B in a MyD88-dependent manner in 
cultured cells (25). Despite these reports, the function of ECRG4 in 
regulating inflammation was previously unknown, in vivo.
On the basis of our current findings, we propose a model (Fig. 6) 
where ECRG4 acts as a sentinel and maintains homeostasis on 
A B C
D E F
G H I
Fig. 5. Loss of ECRG4 increases CD44 expression in vivo. Flow cytometric analysis of blood (A to C) and bone marrow (D to F) from healthy ECRG4 KO mice and litter-
mate controls assessed CD44 expression. (A and D) Representative histograms of CD44 expression on ECRG4 KO (unshaded plot) and WT (shaded plot) neutrophils. (B and 
E) Middle: Number of CD44+ cells within the CD45+CD11b+Ly6G+ neutrophil population, which were not significantly different between the ECRG4 KO and WT mice (n = 6 
mice per group, representative of two independent experiments). (C and F) Right: CD44 MFI on CD45+CD11b+Ly6G+ neutrophils, which show a significant increase in the 
amount of CD44 expressed per cell in the ECRG4 KO mice compared to their WT controls [**P < 0.01 for (C) and *P < 0.05 for (D); n = 6 mice per group, representative of 
two independent experiments]. The expression of ECRG4 and CD44 was correlated in vivo in a wound time course. Gene expression was analyzed from an Affymetrix 
microarray performed on murine cutaneous wounds at multiple times through the wound healing process [Gene Expression Omnibus accession GSE23006; (34)]. Relative 
expression of CD44 (G) and ECRG4 (H) was plotted against time. (I) To visualize changes in expression of CD44 and ECRG4 together, the data were normalized to their 
expression at time 0 (uninjured skin). n = 3 mice for each of the eight time points.
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quiescent leukocytes, including restraining expression of CD44. In 
this model, ECRG4 expression levels determine the amount of CD44 
on the leukocyte surface (Figs. 5I and 6A) to precondition its respon-
siveness to proinflammatory signals, such as TLR agonists. Higher 
levels of ECRG4 expression would result in decreased CD44 and 
thus less anti-inflammatory signaling, such as TLR signal suppres-
sion. After injury, rapid processing of cell surface ECRG4 protein in 
the protease-rich inflammatory milieu releases ECRG4 peptides that 
activate NF-B signaling and amplify local inflammatory responses 
and neutrophil recruitment (Fig. 2E). This proteolytic processing 
depletes cell surface ECRG4 (Fig. 6B), while ECRG4 transcription 
remains low immediately after injury, preventing its replacement 
(Figs. 5H and 6) (33–35). Loss of ECRG4 releases its inhibition of 
CD44. This leads to subsequent increases in CD44 expression at the 
site of injury (Figs. 6C and 5, G and I) (14, 34), which can temper 
proinflammatory responses (9–11) and contribute to the resolution 
of inflammation (2, 12–14). Return of ECRG4 expression at the end 
of the inflammatory phase (Figs. 6D and 5, H and I) decreases CD44 
expression (Figs. 6E and 5, G and I) and restores homeostatic expres-
sion levels. This model is further supported by studies of human 
burn patients, where it has been observed that cell surface ECRG4 
on circulating leukocytes diminishes after injury but returns to house-
keeping levels as patients recover (24). These findings support a role 
for ECRG4 as a sentinel factor, which can both precondition the 
responsiveness of leukocytes through its regulation of CD44 expres-
sion and respond to environmental cues to mediate the kinetics of 
the cutaneous inflammatory response.
While deficient neutrophil mobilization has been shown to in-
hibit wound healing (36, 37), which we observed in the ECRG4 
KO mouse wound, many studies have demonstrated that pro-
longed neutrophil recruitment also results in delayed wound closure 
(38, 39). Earlier studies examined the effect of adenovirus-driven 
ECRG4 overexpression in cutaneous excisional wounds and ob-
served delayed wound healing, possibly through decreased migra-
tion of fibro blasts (33). On the basis of our current studies, we 
hypothesize that ECRG4 overexpression in the wound bed de-
creases CD44 expression, which has been shown to decrease fibro-
blast migration (2). This is supported by the wound closure (Fig. 1A) 
and healing rate (fig. S1A) plots. Initially, rapid wound closure 
occurs through contraction and migration of keratinocytes over 
residual basement membrane at the wound margin. The rate then 
slows, as further reepithelialization requires keratinocyte prolifer-
ation and replacement of the basement membrane by fibroblasts. 
In our model, ECRG4 KO mice have increased CD44 expression, 
which may contribute to the equalization of the healing rate seen 
in the KO mouse after an initial delay that occurs in the first 3 days 
after injury. The potential role of ECRG4 in regulating the func-
tion of stromal cells is outside the scope of this study but will be an 
important area for further investigation. Our current results also 
suggest that an ECRG4- mediated decrease in CD44 expression 
could support excessive neutrophil recruitment and prolonged in-
flammation (2, 14, 32), which also contribute to delayed wound 
closure. Neutrophils are essential for the onset of inflamma-
tion, but the termination of neutrophil influx is equally critical for 
A
C
E
D
B
Fig. 6. Model: ECRG4-CD44 dynamics on leukocytes mediate the kinetics of wound inflammation. (A) On quiescent leukocytes, ECRG4 expression maintains CD44 
at homeostatic levels. Following injury, leukocytes present in the wound are exposed to proteases during the hemostasis and early inflammatory phases. These proteases 
cleave leukocyte cell surface ECRG4 to release active peptides into the wound milieu, which enhance the early local inflammatory response. (B) Black tracing represents 
decreasing cell surface ECRG4 as it is cleaved by wound proteases to release peptides. During this phase, ECRG4 transcription remains low (green tracing), so ECRG4 
protein is not replenished on the cell surface. (C) This loss of ECRG4 removes its inhibition of CD44 expression (red tracing), which results in an increase in cell surface CD44 
receptor (purple tracing). Increased CD44 functions to resolve the inflammatory phase; it is activated by HA fragments in the wound to decrease proinflammatory signal-
ing. As the wound transitions to the proliferative phase, ECRG4 expression resumes (D) and mediates a decrease in CD44 expression (E), returning both ECRG4 and CD44 
cell surface protein to homeostatic levels as wound closure completes and the wound transitions to the remodeling phase. Gene expression data from Fig. 5 (G to I) [Gene 
Expression Omnibus accession GSE23006; (34)] are shown. Protein expression inferred from published reports (14, 35).
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timely resolution of inflammation and prompt restoration of tis-
sue homeostasis (40).
In our study, we demonstrated that ECRG4 is a negative regu-
lator of CD44 expression and a mediator of early inflammatory 
responses. It is interesting to note that the gene encoding ECRG4 is 
epigenetically regulated. Its expression and transcriptional respon-
siveness are down-regulated by hypermethylation of its promoter 
(41), accounting for its diminished expression in multiple human 
cancers (19–21). Many of these same cancers are marked by in-
creased expression of CD44 (42), which is implicated in their prolif-
eration and metastasis and correlates with our findings that ECRG4 
is a negative regulator of CD44. On the basis of our experimental 
observations demonstrating a role for ECRG4 in recruiting neutro-
phils to the site of injury and regulating CD44 expression levels, it is 
interesting to speculate that the epigenetic inhibition of ECRG4 ex-
pression may alter CD44 expression to precondition the inflamma-
tory response, thus driving phenotypic differences in individuals 
based on environmental exposures and aging, which affect promoter 
methylation.
Here, we report that ECRG4 modulates CD44 expression and 
mediates the early neutrophil response to injury, with impaired 
wound repair in its absence. The precise timing of inflammation 
and its resolution in the wound healing response is essential to 
proper wound closure, with unresolved inflammation driving most 
of the chronic wounds. Our current study demonstrates that ECRG4 
is a factor that helps orchestrate the proper timing of the inflamma-
tory response: First, it facilitates and amplifies early inflammation 
but then subsequently supports the expression of factors that are 
essential to injury resolution. A better understanding of its contri-
bution to inflammation preconditioning, susceptibility, and resilience 
will help identify new and sorely needed diagnostic and therapeutic 
strategies to treat cutaneous diseases that are associated with dys-
functional inflammation, including chronic wounds.
MATERIALS AND METHODS
Mice
Heterozygous ECRG4 KO mice were purchased from the Mutant 
Mouse Regional Resource Center supported by the National Insti-
tutes of Health and distributed by the University of California, Davis. 
Briefly, RIKEN complementary DNA 1500015O10 gene coding 
exon 1 was targeted by homologous recombination in B6/129S5 
mixed-background mice. Heterozygous ECRG4 KO mice were then 
backcrossed to C57/BL6 mice (the Jackson Laboratory, no. 000664) 
for five generations and subsequently interbred to generate homo-
zygous ECRG4 KO mice on the C57/BL6 background. Ten- to 
12-week-old littermate mice were used for experiments involving 
ECRG4 KOs, and 10- to 12-week-old C57/BL6 mice purchased 
from the Jackson Laboratory were used as WT mice in experiments 
without ECRG4 KO mice. The University of California, San Diego 
(UCSD) Institutional Animal Care and Use Committee approved 
all animal procedures.
Excisional wound assays
Excisional wound studies were modified from the protocol of Galiano 
et al. (43). Briefly, mice were anesthetized, and dorsal hair was 
clipped and depilated with Nair (Church & Dwight). Full-thickness 
excisional skin wounds were created with a 4-mm biopsy punch. A 
donut-shaped splint with an outer diameter of 10 mm and an inner 
diameter of 6 mm was prepared from a 0.5-mm-thick silicone sheet 
(Grace Bio-Labs, Bend, OR) and sutured on top of the wound using 
4-0 nylon monofilament sterile suture (CP Medical, no. CP-B662B-05). 
Digital photography was used to image each wound daily with a 
ruler included for scale. Wound area was assessed by planimetry 
using the National Institutes of Health ImageJ software. Wounds 
were excised at various time points in some experiments and either 
fixed in 10% buffered formalin for histological analysis or digested 
with a Whole Skin Dissociation Kit (Miltenyi Biotec, no. 130-101-540) 
per manufacturer’s instructions to isolate cells for flow cytometry. 
All experiments were repeated three times, unless otherwise stated, 
with data pooled and total n noted in the figure legends of each 
experiment.
PVA sponge aseptic wound assay
ECRG4 KO mice and WT littermates, or C57/BL6 mice, were used 
for PVA sponge implantation assays (28). PVA sponges (7 mm by 
3 mm; PVA Unlimited Inc.) were sterilized and hydrated with saline. 
Anesthetized mice were shaved, an incision was made on the back, 
and sponges were implanted subcutaneously (28, 29). Incisions were 
closed with a single 4-0 monofilament nylon suture (CP Medical, 
no. CP-B662B-05). In one set of assays, 2 g of sterile synthetic 
CT16 peptide (Phoenix Pharmaceuticals, no. 012-24) in phosphate- 
buffered saline (PBS), or vehicle control, was instilled into the PVA 
sponges before implantation. Infiltrates were isolated from the 
sponge in PBS and analyzed by flow cytometry at indicated time 
points. All experiments were repeated three times, unless otherwise 
stated, with data pooled and total n noted in the figure legends of 
each experiment.
Flow cytometry
Live cells were collected from mouse bone marrow, blood, spleen, PVA 
sponges, or digests of mouse wounds and skin, as described above. 
Cells were incubated with a cocktail of primary antibodies that in-
cluded specified antibodies: anti–CD11b–APC (allophycocyanin)–
Cy7 (BD Pharmingen, 561039; 1:200) and anti–Ly6C–PE (phycoerythrin) 
(BD, eBioscience, 12-5932-80; 1:200) or anti–CD45-VioGreen (Miltenyi 
Biotec, 130-110-803), anti–CD11b-APC-Vio770 (Miltenyi Biotec, 
130-109-288), anti–Ly6C-APC (Miltenyi Biotec, 130-102-341), 
anti–CD44-PE-Vio770 (Miltenyi Biotec, 130-110-085), and anti–
Ly6G–FITC (fluorescein isothiocyanate) (Miltenyi Biotec, 130-107-
912) or Lineage-Biotin cocktail (Miltenyi Biotec, 130-092-613) + 
anti–biotin-FITC (Miltenyi Biotec, 130-113-852), anti–CD48-VioBlue 
(Miltenyi Biotec, 130-102-447), anti–Sca1-PE (Miltenyi Biotec, 130-
116-489), anti–CD150-PE-Vio770 (SLAM) (Miltenyi Biotec, 130-
104-682), and anti–CD117-APC (Miltenyi Biotec, 130-102-492). 
Propidium iodide (Miltenyi Biotec, 130-093-233) exclusion was 
used to determine viable cells. HL60 cells were stained with anti–
CD44-APC (Miltenyi Biotec, 130-113-338). Flow cytometric and 
data analyses were performed on a BD Accuri or Miltenyi Biotec 
MACSQuant10 Flow Cytometer. Data were analyzed with FlowJo 
software (FlowJo LLC), and statistical analysis was performed as 
below. All experiments were repeated three times, unless otherwise 
stated.
Histological analysis
To measure infiltration of Gr1+ cells into the wound, tissues were 
harvested 1 day after injury and frozen in optimal cutting tempera-
ture compound. Standard immunohistochemistry was performed 
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on frozen sections using biotinylated anti–Gr-1 (BD Pharmingen, 
clone RB6-8C5, no. 553125; 1:200) as the primary antibody and 
horseradish peroxidase–conjugated streptavidin (Jackson Immuno-
Research, no. 016-030-084; 1:500) as the secondary antibody. Nuclei 
were counterstained by Mayer’s hematoxylin, and slides that were 
incubated with 1% bovine serum albumin instead of primary anti-
body were used as negative controls. Immunostaining of tissue sections 
was imaged with an FSX100 microscope (Olympus). Identification 
of neutrophils was confirmed by cell and nuclear morphology. Paraffin 
embedding, sectioning, and hematoxylin and eosin (H&E) stains 
were performed by the UCSD Tissue Technology Shared Resource 
Histology Core.
MRSA killing in whole blood
The MRSA strain USA300 LAC was grown on Baird-Parker agar for 
selection, with individual colonies inoculated in tryptic soy broth 
and grown to mid-log phase. Bacteria were washed in sterile PBS. 
One hundred microliters of whole blood from ECRG4 KO or WT 
mice was inoculated with 105 colony-forming units (CFUs) (start-
ing concentration of 1 × 106 CFU/ml), and samples were incubated 
at 37°C for 3 hours. Serial dilutions of the samples and initial inoc-
ulum were prepared in PBS and plated on Baird-Parker agar for 
enumeration. n = 4 mice per group with three technical replicates 
per mouse.
Cell culture
The acute promyelocytic leukemia promyeloblast human cell line 
HL60 (ATCC CCL-240) was purchased from the American Type 
Culture Collection (ATCC) and maintained as recommended in 
Iscove’s modified Dulbecco’s medium with 20% fetal bovine serum 
in an atmosphere of air (95%) and carbon dioxide (5%) at 37°C with 
replacement of medium and passaging at a cell density between 1 × 
105 and 1 × 106 viable cells/ml every 2 to 3 days.
ECRG4 plasmids for stable expression
The full-length human ECRG4 open reading frame was amplified 
by PCR of a pCMV6-XL4-c2orf40 plasmid (OriGene, no. SC104814) 
encoding the human ECRG4 transcript (NM_032411) using primers 
5′-AGTCCTCGAGCCCCGCCGCCATGGCTG-3′ (forward) and 
5′-ATTCGGATCCATGGTTAGTAGTCATCGTA-3′ (reverse) 
and cloned into the Xho I and Bam HI cloning sites of pLVX-IRES-
ZsGreen1 vector (Clontech, no. 632187) to generate a bicistronic 
expression vector (lv-ECRG4) that encodes and expresses ECRG4 
and green fluorescent protein (GFP). Sequencing confirmed iden-
tity of the final plasmid, and the pLVX-IRES-ZsGreen1 plasmid 
without ECRG4 was used to prepare control GFP+ cells (lv-vector). 
Lentivirus was prepared using a lentivirus packaging system (Clontech) 
in Lenti-X 293 cells as described by the manufacturer. Viral titers 
obtained ranged from 2.3 × 107 to 4.0 × 107 used within 3 days on 
target cells.
Stable expression of ECRG4
HL60 cells were transfected using empty (lv-vector) or ECRG4 
(lv-ECRG4) lentivirus using RetroNectin reagent (Takara Inc.) as 
described by the manufacturer. Five days later, GFP+ cells were 
sorted at the cell sorting facility of the Moores Cancer Center at 
UCSD and expanded. Two weeks later, GFP+ cells were selected a 
second time by cell sorting, expanded, and passaged, and aliquots of 
both sorts were frozen in serum–dimethyl sulfoxide.
RNA-seq of gene expression in HL60 cells
In two experiments, vector and ECRG4-expressing HL60 cells were 
cultured in 35-mm, six-well culture dishes at a concentration of 
50,000 cells per well, and RNA was isolated, digested free of DNA, and 
submitted to genomics core laboratories of Cedars-Sinai (Los Angeles) 
for RNA-seq analyses. Bioinformatics analyses were performed from 
FASTQ files, and FPKM (fragments per kilobase of exon model 
per million reads mapped) was determined by AccuraScience (Iowa), 
by the UCSD genomics and Cedars-Sinai core, or with public do-
main resources including STRING (https://string-db.org), Cytoscape 
(https://cytoscape.org), and the iDEP.85 web-based tool for RNA-
seq data analysis and visualization (http://bioinformatics.sdstate.
edu/idep/) as indicated.
Quantitative reverse transcription PCR for CD44
RNA was isolated from HL60 cells using an RNeasy mini kit with 
deoxyribonuclease treatment (Qiagen, no. 74704) according to the 
manufacturer’s recommended procedures, and yields and purity 
were assessed using a NanoDrop2000 Spectrophotometer (Thermo 
Fisher Scientific). Complementary DNA synthesis was accom-
plished with 1 g of total RNA using iScript (Bio-Rad #170-8891) 
according to the manufacturer’s procedures. CD44 gene expression 
was analyzed with CD44 primers purchased from OriGene (no. 
HP200577), and data were normalized to glyceraldehyde-3- 
phosphate dehydrogenase using forward (CATGAGAAGTATGA-
CAACAGCCT) and reverse (AGTCCTTCCACGATACCAAAGT) 
primers purchased from Life Technologies.
Statistical analysis
All statistical analyses were performed using Mstat software (McArdle 
Laboratory for Cancer Research, University of Wisconsin) or GraphPad 
Prism (GraphPad Prism Software Inc.). Unpaired two-sample t test, 
Wilcoxon rank sum test, or two-way analysis of variance (ANOVA) 
with Bonferroni posttest were used. P < 0.05 was considered statis-
tically significant. Data are presented as means ± SD of the mean. 
Sample size calculations were performed with  = 0.05 and  = 0.2. 
First derivative of the wound closure plot in Fig. 1A was performed 
with Prism with default 4 neighbor smoothing.
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Fig. S1. ECRG4 regulates the early response to injury.
Fig. S2. HA signaling pathway from KEGG pathway analysis of RNA-seq data.
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